Sign In
Buy CRL
$232.51
-2.11 (-0.90%)
At Close: Jul 31, 2026
Is Now the Right Time to Hold on to Charles River Stock?
06:51am, Friday, 14'th Feb 2025
CRL's solid prospects in the DSA segment and strategic partnerships present a promising opportunity for investors.
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:06am, Wednesday, 12'th Feb 2025
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions
08:00am, Tuesday, 11'th Feb 2025
WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Deciphex focus on advancing image management solutions, while developing novel AI tools for toxicologic pathology.
CRL Gears Up for Q4 Earnings: Here's What You Need to Know
08:45am, Monday, 03'rd Feb 2025
Growth across the Manufacturing and RMS segments is likely to have contributed to Charles River's fourth-quarter revenues.
Charles River Launches Apollo for CRADL to Boost Research, Stock Rises
09:21am, Wednesday, 22'nd Jan 2025
CRL introduces Apollo for CRADL, integrating the technology stack across its robust portfolio.
Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences
08:00am, Tuesday, 21'st Jan 2025
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River expands Apollo ecosystem, offering bespoke client experiences that enable data-driven decision making.
Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues
12:21am, Tuesday, 21'st Jan 2025
Atara has just announced a CRL by FDA for EBVALLO. EBVALLO is already approved in Europe since December 2022 and the cause of the CRL seems minor and easily addressable. The CRL has a major impact on
Will CRL Stock Gain From Integration of Akron Bio's CSS Product Line?
07:16am, Friday, 17'th Jan 2025
Charles River and Akron Bio collaborate to boost operations by integrating CGMP materials into the Cell Therapy Platform.
Should You Retain Charles River Stock in Your Portfolio Now?
08:30am, Thursday, 02'nd Jan 2025
CRL's solid prospects in the RMS segment and solid financial stability create a favorable outlook for investors.
FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC
09:25am, Tuesday, 17'th Dec 2024
The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR-mutated non-small cell lung cancer.
Why Is Charles River (CRL) Down 8.9% Since Last Earnings Report?
06:49am, Monday, 09'th Dec 2024
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
CRL Stock to Gain From the Global Biotech Incubator Program Launch
09:06am, Friday, 06'th Dec 2024
Charles River's new initiative specifically caters to early-stage biotechnology developers.
Charles River Introduces Global Biotech Incubator Program
08:00am, Thursday, 05'th Dec 2024
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Charles River Incubator Program (CIP), specializing
Is it the Right Time to Hold Charles River Stock in Your Portfolio?
08:21am, Thursday, 28'th Nov 2024
Investors are optimistic about CRL stock due to its strong RMS prospects and inorganic growth efforts.
Charles River (CRL) International Revenue in Focus: Trends and Expectations
10:20am, Monday, 11'th Nov 2024
Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
